192 related articles for article (PubMed ID: 9196151)
21. Patterns of recurrence and survival after lymphadenectomy in melanoma patients: clarifying the effects of timing of surgery and lymph node tumor burden.
Spillane AJ; Pasquali S; Haydu LE; Thompson JF
Ann Surg Oncol; 2014 Jan; 21(1):292-9. PubMed ID: 24052314
[TBL] [Abstract][Full Text] [Related]
22. Surgery and adjuvant radiotherapy for cutaneous melanoma considered high-risk for local-regional recurrence.
Mendenhall WM; Shaw C; Amdur RJ; Kirwan J; Morris CG; Werning JW
Am J Otolaryngol; 2013; 34(4):320-2. PubMed ID: 23375588
[TBL] [Abstract][Full Text] [Related]
23. Combined-modality therapy for patients with regional nodal metastases from melanoma.
Ballo MT; Ross MI; Cormier JN; Myers JN; Lee JE; Gershenwald JE; Hwu P; Zagars GK
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):106-13. PubMed ID: 16182463
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
Lotem M; Merims S; Frank S; Hamburger T; Nissan A; Kadouri L; Cohen J; Straussman R; Eisenberg G; Frankenburg S; Carmon E; Alaiyan B; Shneibaum S; Ozge Ayyildiz Z; Isbilen M; Mert Senses K; Ron I; Steinberg H; Smith Y; Shiloni E; Gure AO; Peretz T
J Immunol Res; 2016; 2016():8121985. PubMed ID: 27294163
[TBL] [Abstract][Full Text] [Related]
25. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
[TBL] [Abstract][Full Text] [Related]
26. Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine.
Berd D
Vaccine; 2003 Jan; 21(7-8):795-7. PubMed ID: 12531362
[TBL] [Abstract][Full Text] [Related]
27. [An individualized prognosis for truncal melanoma? A series of 77 cases].
Martel P; Garrido I; Ferron G; Gangloff D; Chevreau C; Maisongrosse V; Zerdoud S; Simon C; Chapman T
Bull Cancer; 2010 Aug; 97(8):901-7. PubMed ID: 20392688
[TBL] [Abstract][Full Text] [Related]
28. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
Berd D; Maguire HC; McCue P; Mastrangelo MJ
J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
[TBL] [Abstract][Full Text] [Related]
29. Lymphatic flow is mostly preserved after sentinel lymph node biopsy in primary cutaneous malignant melanoma.
Yokota K; Sawada M; Matsumoto T; Hasegawa Y; Kono M; Akiyama M
J Dermatol Sci; 2015 May; 78(2):101-7. PubMed ID: 25771166
[TBL] [Abstract][Full Text] [Related]
30. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
31. Desmoplastic melanoma: a 12-year experience with sentinel lymph node biopsy.
Broer PN; Walker ME; Goldberg C; Buonocore S; Braddock DT; Lazova R; Narayan D; Ariyan S
Eur J Surg Oncol; 2013 Jul; 39(7):681-5. PubMed ID: 23522951
[TBL] [Abstract][Full Text] [Related]
32. Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma.
Paulsen IF; Chakera AH; Drejøe JB; Klyver H; Dahlstrøm K; Oturai PS; Mortensen J; Hesse B; Schmidt G; Drzewiecki K
Dan Med J; 2014 Jan; 61(1):A4741. PubMed ID: 24393586
[TBL] [Abstract][Full Text] [Related]
33. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
Grob JJ; Dreno B; de la Salmonière P; Delaunay M; Cupissol D; Guillot B; Souteyrand P; Sassolas B; Cesarini JP; Lionnet S; Lok C; Chastang C; Bonerandi JJ
Lancet; 1998 Jun; 351(9120):1905-10. PubMed ID: 9654256
[TBL] [Abstract][Full Text] [Related]
34. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
[TBL] [Abstract][Full Text] [Related]
35. The prognosis of melanoma patients with metastases to two or more lymph node areas.
Barth RJ; Venzon DJ; Baker AR
Ann Surg; 1991 Aug; 214(2):125-30. PubMed ID: 1867519
[TBL] [Abstract][Full Text] [Related]
36. Low-dose adjuvant interferon for stage III malignant melanoma.
Inman JL; Russell GB; Savage P; Levine EA
Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
[TBL] [Abstract][Full Text] [Related]
37. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
[TBL] [Abstract][Full Text] [Related]
38. Autologous, hapten-modified vaccine as a treatment for human cancers.
Berd D
Vaccine; 2001 Mar; 19(17-19):2565-70. PubMed ID: 11257393
[TBL] [Abstract][Full Text] [Related]
39. [Use of adjuvant therapy in patients with metastasis of melanoma to regional lymph nodes].
Korovin SI
Klin Khir; 1998; (2):22-3. PubMed ID: 9615073
[TBL] [Abstract][Full Text] [Related]
40. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.
Gershenwald JE; Colome MI; Lee JE; Mansfield PF; Tseng C; Lee JJ; Balch CM; Ross MI
J Clin Oncol; 1998 Jun; 16(6):2253-60. PubMed ID: 9626228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
